DrugInvestigational line

Tofacitinib

JAK inhibitor (JAK1/JAK3)

Response rate
Promising (case series only)
Onset
Weeks
Route
Oral 5-10mg twice daily
Line
Investigational
IgM effect
Suppresses inflammatory biomarkers
Evidence level
amber

Evidence summary

JAK inhibitor showing promise in colchicine-resistant FMF. Three independent case series (6 patients total) reported marked suppression of inflammatory biomarkers and sustained clinical remission. Oral administration is an advantage. Larger controlled trials needed.

Sources (1)

DetailsRecent Advances Group (2025) Familial Mediterranean Fever; Recent Advances, Future ProspectivesPubMed ↗